An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12
Lilly is issuing a public warning about potential safety risks associated with compounded tirzepatide mixed with vitamin B12. As part of our commitment to patient safety, Lilly tested compounded products being marketed to Americans that contain tirzepatide combined with B12 (sometimes referred to
